Vaginal Flora Imbalance
0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Freya BiosciencesDenmark - Copenhagen
3 programsFB101N/A1 trial
FB101N/A1 trial
IVFN/A1 trial
Active Trials
Biolab PharmaBrazil - São Paulo
1 programStryphnodendron Adstringens 3% - once daily post bathN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Biolab PharmaStryphnodendron Adstringens 3% - once daily post bath
Freya BiosciencesFB101
Freya BiosciencesIVF
Freya BiosciencesFB101
Clinical Trials (4)
Total enrollment: 465 patients across 4 trials
Stryphnodendron Adstringens Intimate Soap
Start: Nov 2023Est. completion: Dec 202333 patients
N/AUnknown
FB101 Intervention in Women Screened to Have Vaginal Dysbiosis (Dyscover-3)
Start: May 2023Est. completion: Jan 202597 patients
N/ACompleted
Vaginal Microbiome and IVF Pregnancy Outcome
Start: Mar 2022Est. completion: May 2023301 patients
N/ACompleted
FB101 Intervention in Women Screened to Have Vaginal Dysbiosis
Start: Oct 2021Est. completion: Feb 202334 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.